Search
Now showing items 1-10 of 36
Duration of immune protection of SARS-CoV-2 natural infection against reinfection.
(
Oxford University Press
, 2022 , Article)
The future of the SARS-CoV-2 pandemic hinges on virus evolution and duration of immune protection of natural infection against reinfection. We investigated duration of protection afforded by natural infection, the effect ...
Protection against the omicron variant from previous SARS-CoV-2 infection
(
Massachusetts Medical Society
, 2022 , Other)
Natural infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits strong protection against reinfection with the B.1.1.7 (alpha),1,2 B.1.351 (beta),1 and B.1.617.2 (delta)3 variants. However, the ...
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
(
Massachusetts Medical Society
, 2022 , Article)
The protection conferred by natural immunity, vaccination, and both against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection with the BA.1 or BA.2 sublineages of the omicron (B.1.1.529) ...
Effects of BA.1/BA.2 subvariant, vaccination, and prior infection on infectiousness of SARS-CoV-2 omicron infections.
(
Oxford University Press
, 2022 , Article)
Compared to BA.1, BA.2 was associated with lower RT-qPCR cycle threshold (Ct) value-3.53 fewer cycles (95% CI: 3.46-3.60), signifying higher infectiousness. This may reflect higher viral load and/or longer duration of ...
Variations in respiratory syncytial virus activity following the relaxation of COVID-19 restrictions in Qatar.
(
Oxford University Press
, 2022 , Article)
Despite the relaxation of COVID-19 restrictions in Qatar in October-December 2020, the detection of RSV was reduced ∼25-fold compared with 2019. This dramatic decrease during the typical RSV season could be related to ...
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar.
(
Nature Research
, 2022 , Article)
SARS-CoV-2 Omicron BA.1 and BA.2 subvariants are genetically divergent. We conducted a matched, test-negative, case-control study to estimate duration of protection of the second and third/booster doses of mRNA COVID-19 ...
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
(2021 , Article)
The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with ‘wild-type’ variants in a ...
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar.
(
Massachusetts Medical Society
, 2022 , Article)
Waning of vaccine protection against coronavirus disease 2019 (Covid-19) and the emergence of the omicron (or B.1.1.529) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to expedited ...
Low-level amikacin resistance induced by AAC(6′)-Ib and AAC(6′)-Ib-cr in extended-spectrum β-lactamase (ESBL)-producing Enterobacterales isolated from urine in children
(
Elsevier
, 2021 , Article)
Amikacin is commonly used in children in combination with other agents as a last-resort treatment for severe infections caused by multidrug-resistant Gram-negative bacteria. Amikacin is also prescribed empirically in febrile ...
Trends in fecal carriage of carbapenemase-producing Enterobacterales in children before and after the implementation of international travel restrictions in response to COVID-19
(
Elsevier
, 2021 , Other)
Qatar is located on the northeast coast of the Arabian Peninsula with a large expatriate population comprising 86% of the country's population, most of whom originate from Indian subcontinent countries [1]. International ...